Kezar Life Sciences (NASDAQ:KZR) Upgraded by Wall Street Zen to “Sell” Rating

Kezar Life Sciences (NASDAQ:KZR) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research report on Wednesday, July 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $9.00.

Kezar Life Sciences Stock Down 0.8%

KZR opened at $3.95 on Friday. The firm has a 50 day moving average price of $4.15 and a 200 day moving average price of $4.46. The company has a market cap of $28.91 million, a PE ratio of -0.41 and a beta of 0.61. Kezar Life Sciences has a 1 year low of $3.62 and a 1 year high of $9.18. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.29 and a current ratio of 7.29.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Wednesday, August 13th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.28. Sell-side analysts expect that Kezar Life Sciences will post -4.39 earnings per share for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Woodline Partners LP purchased a new position in shares of Kezar Life Sciences during the 1st quarter valued at approximately $125,000. Dimensional Fund Advisors LP purchased a new position in shares of Kezar Life Sciences during the 4th quarter valued at approximately $217,000. Shay Capital LLC purchased a new position in shares of Kezar Life Sciences during the 4th quarter valued at approximately $398,000. Stonepine Capital Management LLC boosted its stake in shares of Kezar Life Sciences by 69.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock valued at $778,000 after buying an additional 69,859 shares during the last quarter. Finally, BML Capital Management LLC boosted its stake in shares of Kezar Life Sciences by 738.6% during the 1st quarter. BML Capital Management LLC now owns 408,138 shares of the company’s stock valued at $1,992,000 after buying an additional 359,470 shares during the last quarter. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.